Boston Scientific Co. (NYSE:BSX) Shares Sold by Anchor Capital Advisors LLC

Anchor Capital Advisors LLC cut its stake in shares of Boston Scientific Co. (NYSE:BSX) by 13.2% during the 2nd quarter, according to its most recent filing with the SEC. The institutional investor owned 890,402 shares of the medical equipment provider’s stock after selling 135,404 shares during the period. Boston Scientific makes up approximately 1.9% of Anchor Capital Advisors LLC’s holdings, making the stock its 6th largest holding. Anchor Capital Advisors LLC’s holdings in Boston Scientific were worth $68,570,000 at the end of the most recent reporting period.

Other large investors also recently bought and sold shares of the company. Eagle Bay Advisors LLC lifted its stake in shares of Boston Scientific by 542.1% in the first quarter. Eagle Bay Advisors LLC now owns 366 shares of the medical equipment provider’s stock worth $25,000 after acquiring an additional 309 shares in the last quarter. First Foundation Advisors purchased a new position in shares of Boston Scientific during the 1st quarter valued at approximately $25,000. Triad Wealth Partners LLC acquired a new stake in shares of Boston Scientific during the second quarter worth approximately $26,000. RiverPark Advisors LLC bought a new stake in shares of Boston Scientific in the first quarter worth $30,000. Finally, Lynx Investment Advisory acquired a new stake in Boston Scientific in the second quarter valued at $30,000. Institutional investors and hedge funds own 89.07% of the company’s stock.

Boston Scientific Stock Up 0.3 %

BSX opened at $81.60 on Friday. The stock’s 50 day moving average price is $77.40 and its 200 day moving average price is $73.53. The company has a debt-to-equity ratio of 0.44, a current ratio of 1.61 and a quick ratio of 1.14. The stock has a market cap of $119.72 billion, a P/E ratio of 68.57, a P/E/G ratio of 2.71 and a beta of 0.79. Boston Scientific Co. has a 12 month low of $48.35 and a 12 month high of $82.47.

Boston Scientific (NYSE:BSX) last issued its quarterly earnings results on Wednesday, July 24th. The medical equipment provider reported $0.62 EPS for the quarter, beating analysts’ consensus estimates of $0.58 by $0.04. The company had revenue of $4.12 billion for the quarter, compared to analyst estimates of $4.02 billion. Boston Scientific had a return on equity of 16.59% and a net margin of 12.00%. The company’s quarterly revenue was up 14.5% compared to the same quarter last year. During the same period last year, the company earned $0.53 earnings per share. As a group, research analysts predict that Boston Scientific Co. will post 2.4 earnings per share for the current year.

Insiders Place Their Bets

In other Boston Scientific news, EVP Wendy Carruthers sold 6,983 shares of the company’s stock in a transaction that occurred on Thursday, August 1st. The stock was sold at an average price of $74.12, for a total value of $517,579.96. Following the completion of the sale, the executive vice president now directly owns 40,188 shares in the company, valued at $2,978,734.56. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. In the last three months, insiders have sold 20,949 shares of company stock worth $1,627,877. 0.50% of the stock is owned by corporate insiders.

Analyst Upgrades and Downgrades

Several research firms have recently weighed in on BSX. Needham & Company LLC boosted their target price on shares of Boston Scientific from $82.00 to $86.00 and gave the stock a “buy” rating in a research report on Thursday, July 25th. Canaccord Genuity Group upped their price objective on Boston Scientific from $83.00 to $88.00 and gave the company a “buy” rating in a research note on Thursday, July 25th. Robert W. Baird lifted their target price on Boston Scientific from $90.00 to $91.00 and gave the stock an “outperform” rating in a research report on Thursday, July 25th. Truist Financial upped their price target on Boston Scientific from $86.00 to $90.00 and gave the company a “buy” rating in a research report on Tuesday, July 16th. Finally, StockNews.com raised shares of Boston Scientific from a “hold” rating to a “buy” rating in a report on Thursday. Two research analysts have rated the stock with a hold rating, nineteen have issued a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Boston Scientific has a consensus rating of “Moderate Buy” and an average price target of $85.38.

Boston Scientific Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.